The short answer
Two papers from 2000 reported antimicrobial activity for alpha-MSH peptides including the KPV fragment, against Staphylococcus aureus and Candida albicans. The proposed mechanism was an increase in microbial cyclic AMP, which is unrelated to the transporter route that explains the anti-inflammatory work.
Key facts
- Primary paper
- Cutuli M et al., J Leukoc Biol 2000 (PMID 10670585)
- Companion review
- Catania A et al., Ann N Y Acad Sci 2000 (PMID 11268348)
- Organisms tested
- Staphylococcus aureus, Candida albicans
- Concentration range reported
- Broad, including picomolar
- Proposed mechanism
- Increased cellular cAMP in the microorganism
- Mechanistic test used
- Dideoxyadenosine, an adenylyl cyclase inhibitor
- Effect on neutrophil killing
- Enhanced, not reduced
- Human evidence
- None
What was reported
Cutuli and colleagues tested alpha-MSH peptides against two organisms chosen as representative pathogens: the gram-positive bacterium Staphylococcus aureus and the yeast Candida albicans. The peptides significantly inhibited S. aureus colony formation and reversed the enhancing effect of urokinase on colony formation. Small concentrations reduced both the viability and the germ tube formation of C. albicans. Effects were reported across a broad concentration range including the picomolar. The companion review by Catania and colleagues states the fragment result explicitly: alpha-MSH and its fragment KPV showed inhibitory influences against S. aureus and C. albicans.
The proposed mechanism, and how it was probed
The suggested route was that these peptides raise cyclic AMP inside the microorganism. Two observations support it. Cyclic AMP was significantly increased in peptide-treated yeast, and dideoxyadenosine (a potent inhibitor of adenylyl cyclase, the enzyme that makes cyclic AMP) partly reversed the killing activity. Partly is the operative word: a partial reversal implicates the pathway without establishing that it accounts for the whole effect, and leaves room for something else contributing.
Research material referenced
KPV 10mg, third-party HPLC tested
Why this is a separate claim
This is the point most summaries lose. The anti-inflammatory account of KPV runs through PepT1 carrying the tripeptide into a mammalian cell, where it dampens NF-kappaB and MAP kinase signalling. The antimicrobial account runs through raising cyclic AMP inside a bacterium or a yeast. Different organism, different target, different second messenger, different direction. One story is about suppressing a signalling cascade in a host cell, the other about disturbing signalling in a microbe. They are not two faces of one property, and a description that welds them together into a single 'anti-inflammatory and antimicrobial' characteristic is describing something that has not been shown to exist.
The counterintuitive result about neutrophils
There is a standing problem with anti-inflammatory agents: suppressing inflammation tends to reduce the killing of pathogens, which is why immunosuppression and infection travel together. Cutuli and colleagues tested this directly, asking whether alpha-MSH reduced killing of C. albicans and S. aureus by human neutrophils. It did not. Killing was enhanced rather than reduced, which the authors attribute to the direct antimicrobial activity of the peptides. That is an interesting result because the expected direction is the opposite one, and it is the part of this work that would matter most if it held up.
How much weight this literature can carry
Not much on its own, and the reasons are structural rather than a criticism of the work. Both papers are from 2000. Both are in vitro. The specific fragment result for KPV is stated most clearly in a conference-proceedings review rather than in a primary experimental report, which is a weaker place for a load-bearing claim to sit. Two organisms is not a spectrum. And there has been no substantial follow-up establishing an antimicrobial application in the twenty-six years since, which for a promising antimicrobial finding is itself informative.
What is not being claimed
That KPV is an antibiotic, an antifungal, or a treatment for infection of any kind. It is not, it has never been tested as one in a person, and no regulator anywhere has assessed it for anything. This article describes what two papers reported in laboratory organisms. KPV is supplied here as a material for laboratory research only.
Frequently asked questions
Does KPV kill bacteria?
Two in vitro papers from 2000 reported inhibitory effects against one bacterium and one yeast. That is a laboratory observation in two organisms, not a demonstration of antimicrobial activity in any useful sense, and it has not been developed further in the intervening years.
Why would a peptide raise cAMP in a yeast?
Cyclic AMP signalling is ancient and present across kingdoms, including in fungi where it regulates morphological switching such as germ tube formation. A compound that perturbs adenylyl cyclase activity in a yeast is disturbing a real regulatory system. That is a plausible mechanism, though the partial reversal by an adenylyl cyclase inhibitor shows it is not the whole story.
Does the antimicrobial claim depend on PepT1?
No, and that is one reason to treat the two claims separately. PepT1 is a mammalian intestinal transporter. Whatever route these peptides take into a bacterium or a yeast, it is not that one.
Is picomolar activity plausible?
It is what the paper reports and it is unusual: picomolar potency normally implies a high-affinity specific target. It is one of the reasons the finding would be worth replicating with modern methods, and one of the reasons a single 2000 paper is thin ground on which to build a claim.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedCutuli M et al., Antimicrobial effects of alpha-MSH peptides - J Leukoc Biol 2000 (PMID 10670585)pubmed.ncbi.nlm.nih.gov
- PubMedCatania A et al., The neuropeptide alpha-MSH in host defense - Ann N Y Acad Sci 2000 (PMID 11268348)pubmed.ncbi.nlm.nih.gov
- PubMedDalmasso G et al., PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation - Gastroenterology 2008 (PMID 18061177)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More KPV articles
- The Part of the Hormone That Talks to the Receptor Is Not in KPVMelanocortin receptor activation requires the His-Phe-Arg-Trp core, and that tetrapeptide alone is an agonist. KPV is residues 11 to 13 and contains none of it.
- Nanomolar in a Dish Is Not a DoseAlmost every quantitative claim about KPV traces back to immortalised cell lines and mouse models. Here is precisely what each of those can and cannot support.
- What Is KPV? The Tripeptide From Alpha-MSHKPV is Lys-Pro-Val, the C-terminal tripeptide of alpha-MSH, at 342.43 Da. It carries reported anti-inflammatory activity without the pigmentation effects.
- Alpha-MSH: Pigmentation and Inflammation in One HormoneA 13-residue hormone doing two unrelated jobs. Why separating its anti-inflammatory C-terminus from its pigmentation activity was worth attempting.
- How KPV Is Reported to ActReported effects centre on NF-kB signalling and pro-inflammatory cytokine production. Why the mechanism is described intracellularly rather than at a receptor.